Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

QTRX - Quanterix Corp


IEX Last Trade
10.99
0.055   0.500%

Share volume: 11,303
Last Updated: Fri 27 Dec 2024 08:29:30 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$10.94
0.06
0.50%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
8%
Profitability 0%
Dept financing 5%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
3.94%
1 Month
-11.23%
3 Months
-13.04%
6 Months
-14.85%
1 Year
-60.77%
2 Year
-12.07%
Key data
Stock price
$10.99
P/E Ratio 
-12.59
DAY RANGE
$10.64 - $11.10
EPS 
-$1.04
52 WEEK RANGE
$10.50 - $29.70
52 WEEK CHANGE
-$59.51
MARKET CAP 
500.079 M
YIELD 
N/A
SHARES OUTSTANDING 
38.379 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$506,381
AVERAGE 30 VOLUME 
$375,292
Company detail
CEO: Masoud Toloue
Region: US
Website: quanterix.com
Employees: 460
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Quanterix Corporation engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; SR-X and SP-X instruments. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation.

Recent news